move hold eylea guidanc moder
dupix ramp pediatr approv
eylea guidanc concern also surpris
regeneron longer give eylea guidanc expect
previous disclos concern eylea remain core revenu
compon mani year us revenu own compani also
unlik biotech drug price increas eylea difficult unlik given
low-cost competit off-label avastin use addit surpris lack
guidanc sinc eylea continu grow well drug us
dupix competit notic pediatr market key growth
multipl potenti competitor dupix develop includ abbvi
asthma could alter think dupix peak revenu long-term ww
dupix revenu estim vs consensu
estim conserv seem aggress moment given potenti
competit importantli believ dupix need pediatr approv unlock
major revenu potenti may come estim
pediatr market make market
novarti brolucizumab roch may offer competit outsid
novarti brolucizumab roch may offer competit eylea
begin despit show interest difficult interpret data
wet dme result level linger investor concern novarti
brolucizumab focus dose schedul vs week eylea show
patient remain week dose vs eylea histor best
correct visual acuiti bcva week non-inferior eylea numer
inferior manufactur still question roch show improv bcva
vs lucenti phase boulevard studi vs lucenti
dme data similar eylea phase bcva
downgrad hold pt
downgrad rate hold move pt
base concern lack eylea guidanc go forward dupix competit
ahead expect pediatr market uptick level competit
eylea roch dme nv brolucizumab wet would
expect see much downsid rather remain stabl
closer pediatr uptick dupix expect pipelin progress
buy
price close busi februari
biotech discov
invent manufactur commerci medicin
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
consensu vs
believ current dupix estim may aggress clearer verdict
competitor data emerg name oral inhibitor
also believ growth acceler substanti dupix
pediatr approv around time frame sinc pediatr patient make
atop dermat market current dupix estim ww
estim believ estim conserv
also believ consensu number aggress
importantli believ drug like need show superior
efficaci dupix meaning competitor oral formul give
advantag dupix sub-q inject believ push
superior formulari posit ahead dupix drug approv
hold buy target price februari
hold buy target price februari
hold buy target price februari
eylea guidanc puzzl
continu view regn decis longer provid eylea guidanc
januari puzzl especi sinc drug still grow year
year also concern investor interpret lack eylea guidanc
due seriou concern regard competitor drug wet dme
space slow us market expans challeng face
regard contract strategi eylea us agre
three reason actual believ eylea continu grow well
drug nearli revenu us also remind investor
unlik biotech drug increas price due competit
inexpens off-label avastin nonetheless concern lack
eylea guidanc believ weigh share go forward
competit ahead data challeng
expect eylea face competit novarti brolucizumab and/or roch
time frame creat potenti headwind regard
eylea competit howev clinic design data result
brolucizumab make direct comparison eylea somewhat unclear
therefor believ drug may compet eylea
second third-lin set vs front-lin await addit data regulatori
brolucizumab nv less frequent dose manufactur loom
novarti brolucizumab shown interest non-inferior data eylea term
week dose although best correct visual acuiti bcva gain numer
inferior make impact drug unclear time brolucizumab meet
primari endpoint phase hawk harrier studi present
amercian associ opthalmolog meet novemb show non-
inferior eylea week measur bcva studi letter
brolucizumab mg vs letter eylea non-inferior
margin measur averag week letter brolucizumab vs
letter eylea mg non-inferior margin howev
bcva chang brolucizimab numer lower eylea studi
may prompt question retin specialist
novarti also disclos patient abl maintain
dose vs histor eylea importantli yet known
patient receiv brolucizumab dose frequenc reduc everi week vs
discontinu studi
final nv made chang manufactur brolucizumab develop
could complic approv compani must perform test show
new drug product ident older product fda might requir work
patient look pk/pd
hold buy target price februari
hold buy target price februari
novarti also show brolucizumab reduc subretin intraretin fluid
week vs eylea interest secondari consider
visual improv brolucizumab patient also show superior reduct
central subfield thick week interest secondari
consider compar bcva chang
roch interest dme yet differenti vs eylea
roch present phase data boulevard studi diabet
macular edema dme earli februari show letter bcva
improv week compar well letter phase davinci
studi eylea phase studi compar lucenti howev rather
eylea nevertheless await long-term data fulli
assess competit profil vs eylea interestingli bispecif antibodi
vegf announc go forward
program target vegf two separ antibodi believ data
wet roch avenu studi import assess
competit risk eylea meaning improv bcva need
assum dose interv vs eylea
hold buy target price februari
valuationregeneron dcf valuat free yoy depreci capit work capit firm rate termin outstand valu per equiti risk-fre rate beta risk equiti risk-fre rate beta risk growth ratewacctermin growth rate regeneron
hold buy target price februari
hold buy target price februari
fy dermatitisu marketadult patient moder patient moder receiv elig treatment popul dupilumab treatment popul dupilumab pediatric- total patient durat therapi dose per per per annual cost per revenu per us dupilumab demand atop dermat us dupilumab demand atop dermat pediatr discount build us dupilumab revenu atop atop marketadult patient moder patient moder treatment popul treatment popul dupilumab pediatric- total patient durat therapi dose per per per annual cost per revenu per eu dupilumab demand atop dermat eu dupilumab demand atop dermat pediatr discount build drawdown eu dupilumab revenu atop us dupilumab revenu atop eu dupilumab revenu atop total dupilumab revenu atop figur dupix revenu build asthma
hold buy target price februari
uncontrol asthma us marketdiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per dose per per annual cost per revenu per us dupilumab demand uncontrol mod/sever asthma- discount rebates- build drawdown us dupilumab revenu uncontrol mod/sever asthma- fy asthma eudiagnos asthmat moderate/sever asthma asthma uncontrol mod/sever asthma mod/sever asthma laba mod/sever asthma fail laba mod/sever asthma fail uncontrol mod/sever asthma uncontrol mod/sever asthma dupilumab patients- per annual cost per revenu per inventori build drawdown discount rebateseu dupilumab revenu uncontrol mod/sever asthma- regeneron pharmaceut
hold buy target price februari
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentww zaltrap- us ex-u kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- regeneron inc figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold buy target price februari
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total depreci oper profit loss oper profit loss incom expens invest interest incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand regeneron inc regeneron
